ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 82

CKD-506, a Novel Inhibitor of Histone Deacetylase 6 (HDAC6) Has a Therapeutic Potential in Rheumatoid Arthritis and Inflammatory Bowel Disease

Jieun Shin1, Nina Ha1, Daekwon Bae1, Dong-Hyeon Suh1, Yu Jin Jang2, Sehui Shon3, Ji-yeon Baek1, Jae Hyun Jun1, Yong Jae Lee1, Changsik Lee1, Sei-Hwan Kim1, Hosung Yu1, Young Il Choi1, Keun Ho Ryu1, Soung-Min Lee4, Yeong Wook Song2, Su K Seo4 and Seong Kon Kim1, 1Research Institute of Chong Kun Dang Pharmaceutical Corporation, Yongin, Korea, Republic of (South), 2Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, Republic of (South), 3Department of Molecular Medicine and Biopharmaceutical Sciences, Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, Republic of (South), 4Department of Microbiology and Immunology, Inje University College of Medicine, Busan, Korea, Republic of (South)

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Histone Modification, Inflammation, inflammatory bowel disease (IBD) and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis Poster I: The Variable World of Intercellular Signalling

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Autoimmune disease such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) is a chronic inflammatory disorder, significantly limiting quality of life. Even though the dramatic improvement with the new therapeutics had appeared over the past dedicates, there is still huge unmet medical needs. Recently, it was reported that epigenetic regulation is deeply involved in the development of autoimmune disease and that the inhibition of histone deacetylase showed significant immunomodulation. Herein, we introduce highly potent and selective histone deacetylase 6 inhibitor CKD-506 as a novel therapeutic drug for RA and IBD.

Methods: The inhibitory activity and selectivity of CKD-506 for HDAC6 were determined by enzyme assay. The acetylation of tubulin in PBMCs by CKD-506 was determined by western blot. The in vivo efficacy of CKD-506 in RA or IBD was evaluated in adjuvant (AIA)- and collagen (CIA)-induced arthritis or DSS- and CD4+CD45RBhi T cell adaptive transfer-induced colitis animal model respectively. To test the effect of CKD-506 on T cell function, CFSE-labeled effector T cells (Teff) from mouse splenocytes were co-cultured with Treg in the presence of CKD-506 and Teff proliferation was analyzed by flow cytometry. The ex vivo anti-inflammatory effect of CKD-506 was tested with peripheral mononuclear cells (PBMCs) or synoviocytes from RA patients. The effect of CKD-506 on inflammatory mediators in T cell adaptive transfer colitis was screened by real time RT-PCR.

Results: CKD-506 was had a potent and selective inhibitory activity on HDAC6 with an IC50 of 5 nM. CKD-506 highly induced acetylation of tubulin a substrate for HDAC6 in human PBMCs and lymphoid tissue collected from normal rat. In the arthritis animal models, CKD-506 inhibited severity of arthritis in a dose dependent manner and showed strong synergistic efficacy with methotrexate combination. The proliferation of Teff was suppressed by CKD-506. Interestingly, the CKD-506 significantly inhibited TNF a but induced IL-10 production in PBMCs. CKD-506 inhibited IL-1b induced CCL-2, CXCL-8, CXCL-10 production in fibroblast-like synoviocytes from RA patients. In IBD animal models, CKD-506 significantly repressed disease progression and highly inhibited the expression of inflammatory mediators in colon tissues of T cell adaptive transferred colitis animal. (Current status: Phase I in EU, EudraCT number: 2016-002816-42)

Conclusion: The novel HDAC6 inhibitor, CKD-506 had a therapeutic potential in autoimmune disease such as RA and IBD through the inhibition of inflammatory mediators and the regulation of T cell functions.


Disclosure: J. Shin, Chond Kun Dang Research Institute, 2; N. Ha, Chong Kun Dang Research Institute, 2; D. Bae, Chong Kun Dang Research Institute, 2; D. H. Suh, Chong Kun Dang Research Institute, 2; Y. J. Jang, Chong Kun Dang Research Institute, 2; S. Shon, CKD Research Institute, 2; J. Y. Baek, Chong Kun Dang Research Institute, 2; J. H. Jun, Chong Kun Dang Research Institute, 2; Y. J. Lee, Chong Kun Dang Research Institute, 2; C. Lee, Chong Kun Dang Research Institute, 2; S. H. Kim, Chong Kun Dang Research Institute, 2; H. Yu, Chong Kun Dang Research Institute, 2; Y. I. Choi, CKD Research Institute, 2; K. H. Ryu, Chong Kun Dang Research Institute, 2; S. M. Lee, Chong Kun Dang Research Institute, 2; Y. W. Song, CKD Research Institute, 2; S. K. Seo, Chong Kun Dang Research Institute, 2; S. K. Kim, Chong Kun Dang Research Institute, 2.

To cite this abstract in AMA style:

Shin J, Ha N, Bae D, Suh DH, Jang YJ, Shon S, Baek JY, Jun JH, Lee YJ, Lee C, Kim SH, Yu H, Choi YI, Ryu KH, Lee SM, Song YW, Seo SK, Kim SK. CKD-506, a Novel Inhibitor of Histone Deacetylase 6 (HDAC6) Has a Therapeutic Potential in Rheumatoid Arthritis and Inflammatory Bowel Disease [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/ckd-506-a-novel-inhibitor-of-histone-deacetylase-6-hdac6-has-a-therapeutic-potential-in-rheumatoid-arthritis-and-inflammatory-bowel-disease/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ckd-506-a-novel-inhibitor-of-histone-deacetylase-6-hdac6-has-a-therapeutic-potential-in-rheumatoid-arthritis-and-inflammatory-bowel-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology